Oncology
Peritoneal Cancer
0
Pipeline Programs↗
2
Active Trials↗
7
Companies Involved↗
Peritoneal Cancer is an early-stage landscape with 0 programs across 7 companies. The most active players are Pfizer, Accelerated Community Oncology Research Network, Nordic Society of Gynaecological Oncology - Clinical Trials Unit.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
38
clinical trials
Completed24 · 63%
Unknown status6 · 16%
Terminated5 · 13%
Active, not recruiting2 · 5%
Withdrawn1 · 3%
Clinical Trials
Trial Activity
38 trials
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
Active, not recruiting·—·Phase 1·NCT01970722·40 enrolled
Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
Completed·—·Phase 2·NCT02865811·26 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)